175 related articles for article (PubMed ID: 25974405)
1. A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.
Hirakawa A; Wages NA; Sato H; Matsui S
Stat Med; 2015 Oct; 34(24):3194-213. PubMed ID: 25974405
[TBL] [Abstract][Full Text] [Related]
2. Comments on 'A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies'.
Riviere MK; Zohar S
Stat Med; 2016 Feb; 35(3):475-8. PubMed ID: 26757957
[No Abstract] [Full Text] [Related]
3. Identifying a maximum tolerated contour in two-dimensional dose finding.
Wages NA
Stat Med; 2017 Jan; 36(2):242-253. PubMed ID: 26910586
[TBL] [Abstract][Full Text] [Related]
4. Competing designs for drug combination in phase I dose-finding clinical trials.
Riviere MK; Dubois F; Zohar S
Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
[TBL] [Abstract][Full Text] [Related]
5. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
Tighiouart M; Li Q; Rogatko A
Stat Med; 2017 Jan; 36(2):280-290. PubMed ID: 27060889
[TBL] [Abstract][Full Text] [Related]
6. Escalation with overdose control for phase I drug-combination trials.
Shi Y; Yin G
Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
[TBL] [Abstract][Full Text] [Related]
7. Effect of design specifications in dose-finding trials for combination therapies in oncology.
Hirakawa A; Sato H; Gosho M
Pharm Stat; 2016 Nov; 15(6):531-540. PubMed ID: 27539365
[TBL] [Abstract][Full Text] [Related]
8. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
Paoletti X; Kramar A
Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
[TBL] [Abstract][Full Text] [Related]
9. Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials.
Shimamura F; Hamada C; Matsui S; Hirakawa A
J Biopharm Stat; 2018; 28(6):1025-1037. PubMed ID: 29420127
[TBL] [Abstract][Full Text] [Related]
10. A Bayesian case study in oncology Phase I combination dose-finding using logistic regression with covariates.
Bailey S; Neuenschwander B; Laird G; Branson M
J Biopharm Stat; 2009; 19(3):469-84. PubMed ID: 19384689
[TBL] [Abstract][Full Text] [Related]
11. Dose finding with continuous outcome in phase I oncology trials.
Wang Y; Ivanova A
Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
[TBL] [Abstract][Full Text] [Related]
12. A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials.
Hirakawa A; Hamada C; Matsui S
Stat Med; 2013 Nov; 32(26):4515-25. PubMed ID: 23650098
[TBL] [Abstract][Full Text] [Related]
13. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
Guo B; Li Y
Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
[TBL] [Abstract][Full Text] [Related]
14. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
Braun TM; Alonzo TA
Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
[TBL] [Abstract][Full Text] [Related]
15. Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.
Tighiouart M; Piantadosi S; Rogatko A
Stat Med; 2014 Sep; 33(22):3815-29. PubMed ID: 24825779
[TBL] [Abstract][Full Text] [Related]
16. Designs for phase I trials in ordered groups.
Conaway MR; Wages NA
Stat Med; 2017 Jan; 36(2):254-265. PubMed ID: 27624880
[TBL] [Abstract][Full Text] [Related]
17. Keyboard design for phase I drug-combination trials.
Pan H; Lin R; Zhou Y; Yuan Y
Contemp Clin Trials; 2020 May; 92():105972. PubMed ID: 32151751
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II adaptive design for drug combination oncology trials.
Wages NA; Conaway MR
Stat Med; 2014 May; 33(12):1990-2003. PubMed ID: 24470329
[TBL] [Abstract][Full Text] [Related]
19. Comparative review of novel model-assisted designs for phase I clinical trials.
Zhou H; Murray TA; Pan H; Yuan Y
Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
[TBL] [Abstract][Full Text] [Related]
20. Randomized dose-escalation designs for drug combination cancer trials with immunotherapy.
Mozgunov P; Jaki T; Paoletti X
J Biopharm Stat; 2019; 29(2):359-377. PubMed ID: 30352007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
